The TβRII-specific neutralizing antibody LY3022859 (MT-1)demonstrated efficacy against primary tumor growth and metastasis.26,27 Only one potent small-molecule TβRII kinase inhibitor hasbeen disclosed very recently.28 However,in view of the specific subcellular fates and functions of TβRII—comparedto TβRI—with possible activity beyond phosphorylationevents, its targeted degradation is an attractive option. Here, TGFBR2 is linked to neoplasm.